Production (Stage)
Inhibikase Therapeutics, Inc.
IKT
$1.95
-$0.01-0.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 10.51M | 7.19M | 4.19M | 3.08M | 2.75M |
| Gross Profit | -10.51M | -7.19M | -4.19M | -3.08M | -2.75M |
| SG&A Expenses | 5.25M | 5.74M | 1.64M | 1.97M | 2.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.76M | 12.93M | 5.83M | 5.05M | 4.78M |
| Operating Income | -15.76M | -12.93M | -5.83M | -5.05M | -4.78M |
| Income Before Tax | -13.68M | -12.13M | -5.78M | -4.96M | -4.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.68M | -12.13M | -5.78M | -4.96M | -4.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.68M | -12.13M | -5.78M | -4.96M | -4.65M |
| EBIT | -15.76M | -12.93M | -5.83M | -5.05M | -4.78M |
| EBITDA | -15.75M | -12.92M | -5.82M | -5.04M | -4.78M |
| EPS Basic | -0.15 | -0.17 | -0.65 | -0.66 | -0.73 |
| Normalized Basic EPS | -0.10 | -0.11 | -0.41 | -0.41 | -0.46 |
| EPS Diluted | -0.15 | -0.17 | -0.65 | -0.66 | -0.73 |
| Normalized Diluted EPS | -0.10 | -0.11 | -0.41 | -0.41 | -0.46 |
| Average Basic Shares Outstanding | 89.54M | 72.07M | 8.88M | 7.54M | 6.34M |
| Average Diluted Shares Outstanding | 89.54M | 72.07M | 8.88M | 7.54M | 6.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |